Such a great addition to Biobide’s team – Ph.D., MD Calum MacRae of Brigham & Women’s Hospital has taken the role of Biobide’s Scientific Advisor on June 10th, 2018.
Before joining our Scientific Advisory Board, Dr. MacRae trained in Internal Medicine and Cardiology in Edinburgh and London before moving to the Department of Genetics at Harvard Medical School in 1991 for postdoctoral work. He was a postdoctoral fellow with Dr. Mark Fishman, then joined the faculty at the Massachusetts General Hospital in 2000. He became the Chief of Cardiovascular Medicine at Brigham and Women’s Hospital in 2014 and is also an Associate Member of the Broad Institute of Harvard and MIT and a Principal Faculty Member in the Harvard Stem Cell Institute.
Dr. MacRae’s scientific work spans human genetics, cardiovascular developmental biology and drug discovery. His group has used the zebrafish as a tool for high-throughput approaches to genome annotation and understanding disease biology. His laboratory is currently integrating clinical genomics with animal modeling to accelerate therapeutic innovation. Dr. MacRae also leads a large program exploiting genomics digital technologies and learning medical systems to help integrate discovery and clinical care.
We are very happy to welcome Dr. MacRae to Biobide’s Scientific Advisory Board and we are looking forward to taking advantage of his knowledge and expertise in zebrafish, to reinforce Biobide’s scientific team and R&D department to continually create highest quality, precise and scientifically relevant services in the zebrafish alternative model.